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Objective To assess the effects of a 3-year programme aimed at controlling scabies on five small lagoon islands in the Solomon 
Islands by monitoring scabies, skin sores, streptococcal skin contamination, serology and haematuria in the island children.
Methods Control was achieved by treating almost all residents of each island once or twice within 2 weeks with ivermectin 
(160–250 µg/kg), except for children who weighed less than 15 kg and pregnant women, for whom 5% permethrin cream was used. 
Reintroduction of scabies was controlled by treating returning residents and visitors, whether or not they had evident scabies.
Findings Prevalence of scabies dropped from 25% to less than 1% (P < 0.001); prevalence of sores from 40% to 21% (P < 0.001); 
streptococcal contamination of the fingers in those with and without sores decreased significantly (P = 0.02 and 0.047, respectively) 
and anti-DNase B levels decreased (P = 0.002). Both the proportion of children with haematuria and its mean level fell (P = 0.002 
and P < 0.001, respectively). No adverse effects of the treatments were seen.
Conclusion The results show that ivermectin is an effective and practical agent in the control of scabies and that control reduces 
the occurrence of streptococcal skin disease and possible signs of renal damage in children. Integrating community-based control 
of scabies and streptococcal skin disease with planned programmes for controlling filariasis and intestinal nematodes could be both 
practical and produce great health benefits.
Keywords Scabies/drug therapy/complications; Ivermectin/administration and dosage; Permethrin/therapeutic use; Pyoderma/
microbiology; Skin ulcer/microbiology; Streptococcus pyogenes; Nephritis/etiology; Hematuria; Solomon Islands (source: MeSH, NLM).
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Control of scabies, skin sores and haematuria in children in 
the Solomon Islands: another role for ivermectin
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Lessons from the Field
Introduction
Scabies and streptococcal skin disease are a burden in crowded 
communities and are among the most common presentations to 
health services (1). Costs to families and services are high and the 
diseases have long-term implications through post-streptococcal 
renal disease and possibly rheumatic heart disease (2, 3).
In 1991 Taplin et al. reported excellent scabies control 
in a community where everyone, whether or not they had sca-
bies, was very carefully treated with topical permethrin cream. 
With no other treatment, streptococcal pyoderma decreased 
markedly after scabies control. Treating returnees and visitors 
with permethrin maintained these benefits (4). However this 
methodology has not been widely adopted because it is messy, 
time-consuming, and intrusive.
Orally administered ivermectin is active against scabies. 
It is used in the mass annual treatment of millions of people 
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for onchocerciasis (5) and filariasis. Treatment has been found 
to be safe except in people with loaiasis who have high micro-
filaraemia (6). Ivermectin is the usual treatment for scabies in 
domestic animals and has been used successfully for this pur-
pose in humans (7–9). In cases of ordinary scabies, one dose of 
ivermectin is effective (10–12). One-dose treatment is crucial 
to practicality in community settings.
Acute nephritis following pyoderma is well-recognized. 
Subclinical renal damage from multiple skin infections in child-
hood might contribute to the pathogenesis of renal and cardio-
vascular disease in adult life. Recently, in a population where 
end-stage renal disease was extremely common, it was found 
that many factors including scabies and previous nephritis were 
independently associated with a raised urinary albumin-to-
creatinine ratio (13). It is not clear how much of the haematuria 
found in children in developing countries is causally related 
to the many skin infections they experience, although they are 
correlated (14). Haematuria may be a sensitive indicator of 
low-level damage, as tubular reabsorption of protein after minor 
glomerular leakage of red cells and protein may leave haema-
turia as the only sign.
We predicted that scabies control would lead to reduc-
tions in sores, in haematuria, and in the group A streptococci 
(GAS) present in the communities involved.
Methods
Rationale
This was a trial of scabies control in a practical context, to as-
sess the feasibility and effects of treating a whole population at 
once and then maintaining control over a period, with limited 
input, while people went about their normal lives. The islands 
selected were very crowded and scabies common. The island 
location helped define the area and the population to be man-
aged as residents came and went. No continuing comparison of 
treated and untreated groups within the population was pos-
sible because of the underlying principle of the intervention: i.e. 
the need to treat everyone, thus removing all scabies mites and 
preventing reinfection. Orally administered ivermectin was the 
major agent used, because effective topical treatment of large 
numbers is so difficult as to be unacceptable and impracticable. 
We investigated the relationships between scabies, pyoderma, 
renal damage and GAS in sores and on the fingers of children 
in the community. We considered this strategy reasonable and 
likely to reflect the presence of scabies in the population as the 
prevalence in children is generally higher than that in adults. 
Also post-streptococcal disease is largely confined to children. In 
practice, children tend to be more easily available and tolerant 
of imposition than adults.
Setting and population
We studied the people of five small densely-populated islands 
(Sulufou, Foueda, Nuileni, Funafou and Addagege) in the Lau 
Lagoon, Malaita Province, Solomon Islands. Our census in-
cluded 1558 people, about half of whom were on the islands 
at any one time. Many lived elsewhere and visited infrequently. 
The largest island, Sulufou, is about 120 metres in diameter 
and had around 500 people in residence. The other islands were 
similarly crowded. Information was given in the local language 
at public meetings as well as being distributed in print, and the 
communities were asked to consider taking part in the trial. Free 
informed consent was given by volunteers and/or their guard-
ians. The study was approved by the Solomon Island Research 
Ethics Committee and by the Queensland Institute of Medical 
Research Human Research Ethics Committee. The study ran 
from July 1997 until June 2000 and reviews were conducted 
three times per year (Fig. 1). Two retired local female health 
workers who were respected in the community were trained 
and employed to implement the project.
Baseline assessment and treatment
In July 1997, children on Sulufou and Foueda aged 12 years or 
under were examined for scabies and sores and specimens were 
collected from cooperating children. At that first visit the 
whole population of Sulufou was offered treatment, whereas 
no treatment was given to people on Foueda who acted as a 
control population. In November 1997 the children present on 
Foueda and the remaining islands were examined and medica-
tion offered to everyone (see timeline). Information on adverse 
events was sought.
As much of each child’s skin as was accessible without 
embarrassment for children of each age was examined. The ef-
fects on the analysis of a few older children having lesions that 
were confined to their genitals was considered acceptable be-
cause about 90% of people with scabies have lesions on their 
hands and arms (15) and some of the other 10% would have 
visible lesions on the lower limbs and trunk. Scabies in chil-
dren was diagnosed clinically by one investigator on the basis 
of the nature and distribution of lesions (16). These included 
findings such as pruritic papulonodular and vesicular lesions 
on the hands, arms, wrists, feet, thighs, trunk and buttocks. 
Also, a more generalized symmetrical papulonodular eruption 
contributed to some diagnoses, as did acropustulosis in some 
infants. Where findings were suggestive, but not definitive, a 
diagnosis of possible scabies was recorded. In children with-
out apparent active pruritis but with superficial scarring and 
changes in pigmentation from recent scabies, healed scabies was 
recorded. The category of “possible scabies” was used in case 
our intervention had reduced the intensity of infestation in a 
substantial number of children who were actually infected, so 
that a confident diagnosis could not be made. Demonstration of 
mites for diagnosis was not attempted, but mites were recovered 
from lesions during protocol development. Unhealed sores (any 
Fig. 1. Study timeline
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break in the skin), including those from burns and trauma, were 
recorded by site and number. The size and severity of sores was 
not recorded. The hands and arms of all adults were examined 
for scabies at the time of treatment and easily available adults 
were re-examined at the end of the study.
To ensure that coverage was as complete as possible, two 
treatments 2 weeks apart, were offered on each island except 
Addagege. On Addagege, because compliance was complete on 
the first day, only one treatment was given. Throughout the 
study, treatment was offered to returning residents and over-
night visitors whether they had apparent scabies or not.
Medication
Orally administered ivermectin was given at a dose of 160–250 
µg/kg, using 6 mg scored tablets (15–18 kg, 3 mg; 19–27 kg, 
4.5 mg; 28–36 kg, 6 mg; 37–55 kg, 9 mg; 56–74 kg, 12 mg; 
75–100 kg, 15 mg). Children who weighed less than 15 kg were 
treated topically with 5% permethrin cream as were women 
who, in response to queries from a health worker, volunteered 
the information that they were or might be pregnant. Ivermec-
tin treatment was directly observed by a team member. For those 
treated with permethrin, a full tube was supplied by a health 
worker who demonstrated its use and gave instruction in the 
local language. The seven adults with severe generalized scabies 
were treated twice with both ivermectin and permethrin. No 
antibiotic treatment was provided or advised for pyoderma.
Follow-up
At reviews three times per year, children were examined and 
specimens collected as described below. Children were given 
small gifts such as balloons to encourage attendance. Those 
found to have scabies at review were treated, as were their 
household contacts.
Specimens
Swabs from sores and/or fingertips were taken using sterile 
swabs wetted with nutrient broth containing 10% glycerol. 
These were frozen and stored on dry ice within an hour. Blood 
samples were collected from cooperating children aged over 
about 4 years on all islands other than Addegage and the plasma 
frozen. All samples were indexed and stored at –70 °C until 
use. Urine was collected at the initial visit and then monthly on 
all islands except Addagege and Nuileni where the only testing 
after treatment was at reviews. In addition urine collections were 
made every 2 weeks for the first few months from children on 
Sulufou and Foueda to assess the normal pattern of findings. 
Testing was done within hours using commercially available 
urine testing strips. Results for haematuria were recorded as 
negative (0), trace (10), small (25), moderate (80) or large 
(200) cells per microlitre, approximately.
Microbiology and serology
Frozen swabs from sores and from the fingertips of children 
with and without sores were randomly selected from the 
relevant “stored cohorts” (stored cohorts is the term used 
to describe a particular group of samples, e.g. all the stored 
finger-swab samples from children who had no sores early in 
the study) to measure the proportion positive for GAS before 
and after scabies control. Swabs were thawed and plated on 
plain horse-blood agar (HBA) and HBA with gentamicin. After 
incubation at 36 °C with carbon dioxide, representative beta 
haemolytic catalase-negative colonies were plated on HBA with 
a bacitracin disc. Subsequent isolates were typed using a strep-
tococcal typing kit and preserved by freezing.
Anti-streptolysin O titre (ASOT) and anti-DNase B levels 
were measured using commercial kits. Thirty pre-treatment 
serum samples were selected using a list of random numbers 
to compare the mean titre with thirty serum samples randomly 
selected from those collected in 2000. Also, all the pairs of 
samples in cases in which a sample had been collected at base-
line and in January 2000 from the same child, were tested.
Statistical methods
Because many of the same children were seen on numerous 
occasions, a generalized estimating equations approach was used 
for all logistic regression models examining change in the pro-
portion of children with scabies. Negative binomial regression 
analysis (with repeated measures) was used to test the association 
between number of sores per child and time after treatment, 
because number of sores was found to follow an approximately 
negative binomial distribution. The likelihood ratio statistic was 
used to test for statistical significance. Spearman’s correlation 
coefficient was used for quantification. Fisher’s exact test was 
used to compare the proportion of children with scabies and 
sores before and after treatment and the proportions of posi-
tive swab isolates from the earlier and later samples. Geometric 
means were used to compare serological titres. All analyses were 
conducted using SAS statistical software (release 8.0).
The association between proportion of children with 
haematuria ( 25 and  10 cells per microlitre) as well as mean 
red cells per microlitre of urine and time since scabies treatment 
were analysed using weighted least squares linear regression to 
draw the lines of best fit. Ordinal logistic regression was used 
to assess the significance of the overall change in concentration 
of red cells per microlitre over time.
The relationship between sores and haematuria was ex-
amined by correlating the number of sores with the numbers 
of red blood cells/microlitre at the time of the sore review and 
also in urine collected a month later. Results from all visits were 
pooled for this analysis. Non-parametric methods (Spearman 
coefficient) were used to calculate correlations and logistic 
regression used to assess statistical significance. Results were 
analysed using both  25 red cells/microlitre and  10 red 
cells/microlitre to define haematuria.
Neither the Thrasher Research Fund, nor Merck Sharp 
and Dohme had any part in study design, data collection and 
analysis, the preparation of the manuscript or in submission 
for publication.
Results
Five hundred and forty-one different children were seen in the 
course of the study; 258 (48%) were seen four times or more 
(frequencies: 142 × 1, 75 × 2, 66 × 3, 67 × 4, 68 × 5, 59 × 6, 
45 × 7 and 19 × 8 times). The estimated age distribution of 
the subjects stayed relatively constant because as older children 
dropped out infants and toddlers were being added.
Treatment efficiency
The prevalence of scabies fell dramatically on all the islands 
after treatment (Fig. 2), from a mean of 25%, 66 of 267 (95% 
CI, 20–30), to a steady level of less than 1%, 2 of 305 (0.7%; 
95% CI, 0.1–2.2), P < 0.001. No adverse events were noted.
Over 95% of the people who were present on the islands 
during the treatment period were treated; just over half of them 
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Fig. 2. Number of children with scabies by approximate months after treatmenta
WHO 04.190
Time in months after scabies treatment
30
a The fall in the proportion of children with scabies is significant (P < 0.001). As treatment began 4 months earlier on Sulufou, the results at 36 months refer only to Sulufou children,
about half the total.
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Sulufou only
twice. On Sulufou where the census population was 743, 228 
were away, 494 were treated once or twice and 21 declined or 
avoided treatment. Ten per cent of the children said to have 
scabies or possible scabies at baseline were diagnosed as having 
scabies or possible scabies at the next review, 4 or 5 months 
later. Of these possible failures, half were among the 24% 
of children treated topically with permethrin. On Addagege 
a single treatment was similarly effective although half the 
population had scabies before the treatment was given. Here, 
all ten children with scabies who were treated with ivermectin 
and seen again 4 months later were cured.
Although not all the ivermectin distributed was actually 
swallowed (we found some partially dissolved tablets on the 
ground), few re-treatments were required. Most cases of sca-
bies seen at reviews were in children who had returned from 
elsewhere and had not been treated in the interim.
Controls
On Foueda, two pre-treatment observations were made, in July 
and November 1997. At the time of the first observation, 23% 
(14/61) of the children seen had scabies or possible scabies; 14 
had healed scabies. The proportion of children with scabies and 
those with sores did not change significantly between July and 
November (26%; 12/46).
Scabies in adults
At the time of treatment about 20% (81 of 374) of the adults 
for whom findings were recorded had scabies. At the last review 
when the hands and arms of about 250 adults from all islands 
were examined only two, neither of whom had been treated, 
were diagnosed as having scabies.
Sores
The proportion of children with sores decreased from 40%, 
91 of 226 (95% CI, 34–47) to 22%, 35 of 162 (95% CI, 
16–28; P < 0.001) and the mean number of sores per affected 
child decreased with time (Table 1). The fall was statistically 
significant, the correlation with time being –0.15 (P for trend 
< 0.0001). The proportion of children with sores on the more 
trauma-prone lower limbs stayed at about 20% (33 of 162). The 
number with sores on the upper body, including those with 
sores on both the upper and lower body, fell from 16%, 34 of 
215 (95% CI, 11–21) to less than 5% by the end of the study 
(3.1%, 5 of 162 (95% CI, 1–7)) P < 0.001.
At the review in January 2000, many children had circu-
lar marks on their skin that were said to have followed recent 
superficial blisters: probably due to impetigo which, in these 
conditions, is usually streptococcal (17). No change in scabies 
was reported.
Microbiology and serology
In stored samples from sores, randomly selected from those col-
lected in 1997, November 1998 and January 2000, GAS grew in 
92%, 90% and 84%, respectively (P = 0.52). GAS were found 
in 61% of finger swabs taken from children with sores early in 
the study whereas, of the swabs taken later in the study, only 
32% were positive (P = 0.02) (Table 2). Of the fingertip swabs 
taken from children without sores, 24% (9/38) of those taken 
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early in the study contained GAS, whereas only 5% (2/38) of 
those taken later were positive (P = 0.047, all tested with Fisher’s 
exact test) (Table 2). The total numbers of swabs from sores and 
fingers tested during the study were 153 and 321, respectively. 
Ninety-eight per cent (150) of all samples from sores tested 
grew streptococci, 92% (141) grew GAS; of the fingertip swabs 
38% (122) grew streptococci and 30% (96) GAS.
The geometric means (GMs) of the ASOT and anti-
DNase B titres in random serum samples collected before treat-
ment and at the end of the study were not significantly differ-
ent (n = 30 for each group). The means for ASOT titres from 
samples taken early and later in the study were 184 and 189; for 
anti-DNase B titres the means were 316 and 359, respectively. 
However, in the paired samples from the children who provided 
sera at the time of treatment and again at the end of the study 
(n = 33), there was a significant fall (P = 0.002) in the titre of 
anti-DNase B from 512 (95% CI, 404–650) to 346 (95% CI, 
278–428). The GM for the ASOT titres in the same samples 
did not change significantly (178 in samples taken early in the 
study and 203 in those taken later). Unfortunately, for logistical 
reasons the events surrounding the possible impetigo outbreak 
in late 1999 could not be examined.
Haematuria
There was a significant decrease in the proportion of children 
with haematuria at both  25 cells/microlitre (P = 0.002) and 
 10 cells/microlitre (P < 0.001), despite wide variation from 
month to month. The mean levels of haematuria (Fig. 3) also 
fell with time (P < 0.001). There was however a sharp rise in 
the mean haematuria levels in the period prior to the January 
2000 review when the marks left by the possible impetigo 
outbreak were noted.
Where a child in a household was found to have haema-
turia ( 25 cells/microlitre) the odds ratio of another child in 
that household having haematuria at the same time was 2.04 
compared with children overall (95% CI, 1.11–3.75, P = 0.02).
The number of sores per child was not significantly re-
lated to haematuria measured at the same review (1124 pairs 
of data examined; correlation 0.02; P = 0.69). However, the 
number of sores was related to haematuria a month later; cor-
relation 0.09; P = 0.03 (573 pairs of pooled data). Of the 573 
Table 1. Percentage of children with sores at baseline and after scabies treatment, percentage with 1–4 and > 4 sores and 
mean number of sores per childa
Time examined Total number of  > 4 sores (%) 1–4 sores (%) Any sores (%) Mean sores per child 
 children examined    (standard error)
Baseline  230 5  35  40  1.03 (0.11)
4 months  236b  5  32  37  0.92 (0.12)
8 months  257  4  26  30  0.85 (0.15)
12 months  214c  3  31  34  0.78 (0.12)
16 months  196  4  31  35  0.72 (0.10)
21 months  264c  2  25  27  0.50 (0.07)
26 months  308  1  28  29  0.49 (0.06)
31 months  303  2  20  22  0.46 (0.07)
36 months  163  3  18  21  0.48 (0.11)
a  Correlation of number of sores with approximate number of months after treatment= –0.15, P-value from Spearman correlation < 0.0001.
b  Two of the 236 children had sores, but the number of sores was not counted.
c  One child in this group had sores, but the number of sores was not counted.
children in question only 20 had more than four sores, three of 
whom (15%) had  25 cells per microlitre of urine, compared 
to 12% (66) in those with up to four sores, not a marked differ-
ence. However, 65% (13) of the children with more than four 
sores had  10 cells/microlitre of urine, whereas in children 
with four sores or fewer only 19% (101) had haematuria at 
this level a month after the sores were diagnosed (P = 0.0015; 
Fisher’s exact test).
Discussion
The precipitous fall in the prevalence of scabies among treated 
children on Sulufou, and the fact that infestation in children 
on Foueda remained unchanged until after their treatment later 
in the study, provide strong evidence that the control of scabies 
was a direct result of treatment. The effect was greater than that 
reported in Papua New Guinea following a dose of ivermec-
tin (18), probably because the whole population was treated. 
Another study reported that 95% of cases of scabies among 
1500 prisoners were cured when a single dose of ivermectin was 
given to the whole jail population (10). In our study, scabies 
was greatly reduced by the initial treatments and reinfection was 
largely prevented by treating returnees and visitors. In the late 
stage of the study, scabies was found only on untreated people 
showing that transmission within the population was minimal. 
On the smaller islands, treatment of returnees and visitors was 
less immediate and less thorough than on Sulufou where a treat-
ing staff member was resident. Nevertheless, scabies control was 
maintained on these islands despite the delay and movement 
of people. This raises the possibility that an annual treatment 
in situations when no active interim treatment can be provided 
might also be an effective strategy.
Ivermectin has major advantages over topical treatments. 
It is far more convenient to use and there is no problem with 
incomplete application or with the treatment being washed 
off. Also ivermectin has prolonged activity (a single dose made 
pigs resistant to applied Sarcoptes for a week and a human who 
had taken ivermectin was lethal to feeding mosquitoes for a 
longer period) (19, 20), suggesting there may be considerable 
flexibility in the time available to complete community treat-
ment. Because of the safety of ivermectin at a dose of 400 µg/kg 
(11) and because there was a lower rate of cure of scabies when 
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Table 2. Streptococcal isolates from sores and fingertips, early and late in the study
Time  Swabs tested  GASa isolated (%) Other streptococci  No streptococci 
   isolated (%) isolated (%)
Swabs taken from sores before and after 
scabies controlb
1997  85  78  (92)  19  (22)  3  (4)
November 1998  30  27  (90)  18  (60)  0
January 2000  25  21  (84)c  11  (44)  1  (4)
Finger swabs taken from children with sores  
before and after scabies controld
1997  36  22  (61)  7  (19)  12  (33)
1999; 2000  28  9  (32)e  8  (29)  15  (54)
Finger swabs taken from children without  
sores before and after scabies controlf
1997  38  9  (24)  3  (8)  26  (68)
2000  38  2  (5)g  2  (5)  34  (89)
a  GAS, group A streptococci.
b  There was no significant change in the proportion of sores containing GAS.
c  P = 0.52 (January 2000 vs 1997).
d  The proportion of children with sores who had GAS on their fingers declined.
e  P = 0.02.
f  The proportion of children without sores with GAS on their fingers fell.
g  P = 0.047; all tests Fisher’s exact test.
ivermectin was administered at 100 µg/kg (21), the dose of 
approximately 200 µg/kg employed in this study should not 
be reduced. Higher doses might be advantageous as they may 
lessen the chance of resistance emerging. The reliability, palat-
ability and historical safety of oral ivermectin suggest that data 
on its safety in children below the present lower limit of 15 kg 
body weight should be collected. The present 3 mg tablet broken 
in half would be practical for administration to children with 
body weights down to 7.5 kg.
Drug safety is particularly important in situations where 
many unaffected people are treated. We are aware of no reports 
of idiosyncratic responses to ivermectin in humans, although 
there are reports of a genetic susceptibility in dogs (22). Although 
no problems were reported in a study of pregnant women in 
Africa (5), we did not use ivermectin in women known to be 
pregnant or who were possibly pregnant. No adverse events 
were noted in this study.
Although the children appeared to be clean and spent 
much time in the sea, almost one third of all the finger swabs 
tested contained GAS, emphasizing the high level of exposure of 
the children to this organism. Taplin found similar levels (25%) 
among children living with pyoderma in an earlier study (D. 
Taplin, personal communication, 2003). Hand contamination 
is likely to be central in the transfer of strains of GAS from child 
to child, and in the infection of skin injuries, slowing their 
healing. Sores and scratches are the likely reservoir of GAS in 
this situation, as normal skin is not usually a source (23), but 
scabies, because it leads to constant scratching and rubbing, 
must be important in spreading the organism and contaminat-
ing the fingers as well as damaging the skin. Evidence for this 
comes from the significant decrease in the number of sores and 
in contamination of fingertips with GAS that was observed in 
our study after scabies control in the absence of any specific 
treatment for sores. Similar findings relating to sores have been 
reported by others (4, 10). However, in our study, because many 
sores infected with GAS remained, the effects of scabies control 
on the epidemiology of GAS might have been hastened and in-
creased by treating children who had sores using penicillin.
The reduction in haematuria seen to occur in parallel 
with the decline in sores, the significant correlation between 
the presence of sores and haematuria a month later, the tem-
poral clustering of children with haematuria in households and 
the peak in incidence of haematuria that followed a probable 
outbreak of impetigo, all provide support for a post-infec-
tious cause for many of the cases of haematuria we found. 
The significant reduction in the proportion of children with 
haematuria may reflect a change in low levels of specific post-
streptococcal damage.
The changes in incidence of scabies, sores and haema-
turia that followed scabies control on the five islands probably 
resulted directly from the intervention, although other factors 
may also have contributed. There were no changes in the clini-
cal services available, or in access to them, over the study period 
to explain the observations. A concomitant fall in the average 
nephritogenicity of the GAS strains circulating in the com-
munities is an unlikely explanation for the progressive fall in 
haematuria, as, in crowded circumstances such as these, many 
strains are circulating (24). The reduction in the prevalence of 
sores, in GAS on the hands and fingers, and in haematuria that 
we demonstrated following scabies control, might, if extended 
over the whole of childhood, make a substantial difference to 
the accumulation of renal damage.
The programme we used to demonstrate the effects of 
scabies control would not be practical in most of the countries 
in which scabies and streptococcal skin disease are important 
because treatments frequently fail without very careful supervi-
sion. Also, the expense of the drugs and of initiating a specific 
community-based programme for this disease complex would 
be competing with more pressing health needs. However, our 
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Fig. 3. Mean level of red cells in the urine after scabies treatmenta
WHO 04.189
Time in months after scabies treatment
40
a A possible reason for the peak 2 years after treatment is given in the text.  The decline in mean concentration of red cells represented by the regression line is significant (P < 0.001).
The number of urine samples tested at each point has been superimposed on the graph.
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collaborators report that the prevalence of scabies remains 
very low on Sulufou in 2004 despite there having been no 
further input since our intervention. This suggests that the 
programmes proposed for control of filariasis, which deliver 
either ivermectin or diethylcarbamazepine (DEC) and alben-
dazole annually (25), may well provide effective scabies control 
when ivermectin is used.
The ivermectin and albendazole combination given 
annually to whole communities may well control a number 
of significant health problems including: scabies, hookworm, 
strongyloides and other intestinal nematodes, as well as filariasis. 
The added impact on skin disease and post-streptococcal disease 
and on strongyloides and trichuris infection, would justify a 
preference for using ivermectin rather than DEC in these pro-
grammes. Also, the parallel health benefits may justify its use 
in areas in which filariasis is not a concern, and, if the drugs 
for this purpose were donated, their use could prove sustain-
able in countries with limited health budgets. Further studies 
are recommended.  O
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Résumé
Lutte contre la gale, les lésions cutanées et l’hématurie chez les enfants des Îles Salomon : un autre 
rôle pour l’ivermectine
Objectif Évaluer les effets d’un programme sur 3 ans de lutte 
contre la gale sur cinq petites îles lagunaires des Îles Salomon 
à travers la surveillance de la gale, des lésions cutanées, de la 
contamination de la peau par des streptocoques, de la sérologie 
et de l’hématurie chez les enfants de ces îles.
Méthodes Les responsables du programme sont venus à bout de 
la gale en traitant presque tous les habitants de chaque île une 
à deux fois en l’espace de deux semaines avec de l’ivermectine 
(160 à 250 µg/kg), à l’exception des enfants pesant moins 
de 15 kg et des femmes enceintes, chez lesquels ils ont utilisé 
de la crème à 5 % de perméthrine. Ils ont fait obstacle à la 
réintroduction de la gale en traitant les habitants revenant d’un 
déplacement et les visiteurs, qu’ils présentent ou non une gale 
de façon manifeste.
41Bulletin of the World Health Organization | January 2005, 83 (1)
Lessons from the Field
Gregor Lawrence et al.   Ivermectin in control of scabies, skin sores and haematuria, Solomon Islands 
Résultats La prévalence de la gale est passée de 25 % à moins 
de 1 % (p < 0,001), celle des lésions de 40 % à 21 % (p < 0,001), la 
contamination des doigts par des streptocoques chez les personnes 
présentant ou non des lésions a diminué significativement (p = 
0,02 et 0,047, respectivement) et les concentrations d’antiDnase-
B ont baissé (p = 0,002). La proportion d’enfants souffrant 
d’hématurie et la valeur moyenne de cette proportion ont chuté 
(p = 0,002 et p < 0,001, respectivement). On n’a observé aucun 
effet secondaire des traitements.
Conclusion Les résultats montrent que l’ivermectine est un 
agent efficace et pratique dans la lutte contre la gale et que la 
prévention de cette maladie réduit la fréquence des infections 
cutanées streptococciques et des signes éventuels de lésion 
rénale chez les enfants. L’intégration aux programmes planifiés de 
lutte contre la filariose et les nématodes intestinaux de la lutte à 
l’échelle de la communauté contre la gale et les infections cutanées 
streptococciques pourrait constituer une option à la fois pratique 
et très bénéfique pour la santé.
Resumen
Control de la sarna, las lesiones cutáneas y la hematuria en los niños en las Islas Salomón: otra utilidad 
de la ivermectina
Objetivo Evaluar los efectos de un programa de 3 años 
encaminado a combatir la sarna en cinco pequeños atolones de 
las Islas Salomón, procediendo para ello a vigilar en la población 
infantil de las islas las manifestaciones de esa enfermedad, las 
lesiones cutáneas, la contaminación de la piel por estreptococos, 
la serología y los casos de hematuria.
Métodos Se logró controlar la enfermedad tratando a casi 
todos los residentes de cada atolón con ivermectina (160–250 
µg/kg) una o dos veces en un periodo de dos semanas, salvo en 
el caso de los niños que pesaban menos de 15 kg y las mujeres 
embarazadas, a quienes se administró pomada de permetrina al 
5%. Se evitó la reintroducción de la sarna tratando a los residentes 
que regresaban del exterior y a los visitantes, tuvieran o no signos 
evidentes de sarna.
Resultados La prevalencia de sarna se redujo de un 25% a menos 
del 1% (P < 0,001); la prevalencia de lesiones cutáneas lo hizo de 
un 40% a un 21% (P < 0,001); la contaminación estreptocócica de 
los dedos, entre personas con y sin lesiones, disminuyó de forma 
significativa (P = 0,02 y 0,047, respectivamente), y los niveles de 
anti-DNasa B se redujeron (P = 0,002). Descendieron también 
tanto la proporción como el nivel medio de niños con hematuria 
(P = 0,002 y P < 0,001, respectivamente). No se detectaron 
efectos adversos de los tratamientos.
Conclusión Los resultados indican que la ivermectina es un 
agente eficaz y práctico contra la sarna y que las medidas de 
control reducen la aparición de lesiones cutáneas estreptocócicas 
y los posibles signos de daño renal en los niños. La integración 
del control comunitario de la sarna y las lesiones cutáneas 
estreptocócicas junto con programas planificados de control de la 
filariasis y los nematodos intestinales podría ser una opción práctica 
y, al mismo tiempo, generar grandes beneficios sanitarios.
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